More than two years after the public debut of ChatGPT, software companies still haven’t found a compelling way of charging ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...